The Regulator

3.6 billion dollars: that is the size of the Medicare drug-plan subsidy the Trump administration is letting expire after this year, a decision that will raise the standard 2027 premium for millions of beneficiaries with standalone prescription drug coverage. The Centers for Medicare and Medicaid Services confirmed July 28, 2026 that it will discontinue the Part D Premium Stabilization Demonstration at the end of calendar year 2026, ending a program that has used a 15 dollar per-beneficiary direct subsidy and a 35 dollar cap on year-over-year increases to hold down standalone Medicare Part D premiums since 2025; the Government Accountability Office estimated the demonstration’s total cost at more than 9.8 billion dollars across 2025 and 2026, with this year’s subsidies alone running about 3.6 billion dollars. CMS said its review of insurers’ 2027 bids found plan sponsors now have enough experience under the Inflation Reduction Act’s redesigned Part D benefit to price their plans without the extra support, and an administration official said the subsidy had given insurers an incentive to raise premiums because the government absorbed much of the added cost; the national average monthly bid amount for 2027 is 296.05 dollars and the base beneficiary premium rises from 38.99 dollars to 41.33 dollars. CMS said roughly 30 percent of beneficiaries will see monthly increases under 10 dollars and about a quarter will see premiums hold steady or fall. Confidence: dropped, since CMS’s own fact sheet returned an access block for this issue and this account rests on Wall Street Journal-sourced wire reporting from U.S. News and Yahoo Finance that quotes the agency’s figures and reasoning directly. Sources: Trump Administration to End Medicare Premium Subsidy Program, U.S. News and World Report, Trump Administration to End Drug Plan Subsidy for Medicare, Yahoo Finance.

203 million dollars: that is how much a federal-state Medicaid fraud task force says it stopped from going out the door in its first 88 days of operation. CMS announced July 28, 2026 that the Medicaid Fraud War Room, launched April 23, 2026 in coordination with the White House Task Force to Eliminate Fraud, has coordinated enforcement action against 50 unique high-risk Medicaid providers whose billing represents more than 203 million dollars in payments now subject to federal exclusion and state enforcement. The war room pairs CMS, the Department of Health and Human Services’ Office of Inspector General, state Medicaid agencies and federal law enforcement on the same real-time data, letting agencies flag a suspect provider before more taxpayer money goes out rather than clawing payments back afterward. Confidence: High on the figures and program description, since CMS’s own press release states them directly. Source: CMS Medicaid Fraud War Room Stops More Than $203 Million in Improper Payments During First 88 Days, Centers for Medicare and Medicaid Services.

528.6 million dollars: that is the size of the federal contract a private prison operator is banking on to reopen a decade-dormant Colorado prison as an immigration detention center, a plan a new lawsuit says skipped the town’s own zoning rules. Together Colorado, a multifaith advocacy group, and Weld County resident Janet Carlson sued the town of Hudson, Colorado in state court July 23, 2026, arguing the town council and planning commission cannot let the GEO Group reopen the long-shuttered Hudson Correctional Facility, since rebranded the Big Horn Facility, as a roughly 1,200-bed U.S. Immigration and Customs Enforcement detention center without the conditional-use zoning approval the site’s prior operator obtained in 2008. GEO signed a five-year, 528.6 million dollar federal contract July 9, 2026 that would nearly double Colorado’s immigration detention capacity to about 2,700 beds; Hudson officials say federal contracting authority preempts the town’s zoning power over the site. Confidence: High on the contract’s size and the lawsuit’s filing and arguments, since GEO’s own contract disclosure and multiple independent Colorado outlets’ direct reporting on the complaint corroborate them; Low on how a court will rule, since no hearing date had been set as of this issue. Sources: Faith group, Weld County resident sue Hudson over ICE detention center zoning issue, Colorado Newsline, Colorado town sued over ICE detention center, The Colorado Sun.

7 days: that is how long a Senate committee’s vote on the Trump administration’s pick to run the Centers for Disease Control and Prevention has been delayed, and it is now set for tomorrow alongside a bill that would extend federal privacy rules to health apps and wearables for the first time. The Senate Health, Education, Labor and Pensions Committee postponed a July 23, 2026 vote on Erica Schwartz’s nomination as CDC director after Senator Lisa Murkowski, a Republican whose vote Chairman Bill Cassidy needed, was absent for a family emergency; the committee rescheduled the vote for July 30, 2026, alongside Sean Kaufman’s nomination as the Department of Health and Human Services’ Assistant Secretary for Preparedness and Response and a slate of 10 bills, including the Health Information Privacy Reform Act, which would direct the Department of Health and Human Services, working with the Federal Trade Commission, to write privacy, security and breach-notification standards for health data collected by apps, wearables and other services the Health Insurance Portability and Accountability Act does not currently cover. Schwartz, a former deputy surgeon general and Coast Guard rear admiral, had a confirmation hearing July 15, 2026. Confidence: High on the schedule, nominees and bill provisions, since the committee’s own hearing notice and the bill’s text on Congress.gov confirm them directly; no rating on any vote’s outcome, since none has occurred as of this issue. Sources: Nominations, S. 5038, S. 5046, S. 2511, S. 3010, S. 3589, S. 4097, S. 4689, S. 3333, S. 4965, and S. 3097, Senate Committee on Health, Education, Labor and Pensions, S.3097, Health Information Privacy Reform Act, Congress.gov.

3 to 5 percent: that is the share of American cancer patients who ever enroll in a clinical trial, and the FDA just finalized three guidance documents aimed at the eligibility rules that screen most of the rest out. The FDA’s Oncology Center of Excellence finalized guidance on cancer clinical trial eligibility criteria covering laboratory values, washout periods and concomitant medications, and performance status, all announced in the Federal Register July 28, 2026; the documents recommend against unjustified narrow lab-value cutoffs, unnecessary drug washout periods and rigid physical-functioning thresholds that the agency says can exclude patients who could safely enroll and benefit, without changing the science being tested. Published research has found roughly half of cancer patients meet the strictest published eligibility criteria for a trial in their disease, with additional patients eligible only under broadened criteria, and FDA has said unnecessarily restrictive criteria slow enrollment and produce results that do not reflect the patients who will ultimately take an approved drug. Confidence: High on the guidances’ existence and content, since the Federal Register notices and FDA’s own guidance documents confirm them directly; Low on how much trial enrollment or diversity will change in practice, since the guidance is a recommendation, not a binding rule. Sources: Cancer Clinical Trial Eligibility Criteria: Laboratory Values, Federal Register, FDA finalizes three guidances to broaden cancer clinical trial eligibility, RAPS.